avgemsi: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920	NDA	Avyxa Pharma, LLC	83831-123-01	1 VIAL, MULTI-DOSE in 1 CARTON (83831-123-01) / 26.3 mL in 1 VIAL, MULTI-DOSE	2025-08-03
Avyxa Holdings	AVGEMSI	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	219920	NDA	Avyxa Pharma, LLC	83831-124-01	1 VIAL, MULTI-DOSE in 1 CARTON (83831-124-01) / 52.6 mL in 1 VIAL, MULTI-DOSE	2025-08-03
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 18, 2025

Introduction

The pharmaceutical landscape is a complex ecosystem involving multiple stakeholders, including manufacturers, suppliers, distributors, and regulatory authorities. Among these, suppliers play a critical role in ensuring the availability, quality, and continuity of drug production. This article examines the suppliers for AVGEMSI, a pharmaceutical product that has garnered attention in recent years. While there is limited publicly available information specific to AVGEMSI, industry insights, patent data, and strategic supplier trends can offer a comprehensive understanding of the sourcing landscape relevant to this drug.

Understanding AVGEMSI and Its Market Context

AVGEMSI, known within pharmacological circles for its innovative formulation, is part of a broader therapeutic category. Obtaining raw materials and active pharmaceutical ingredients (APIs) with high purity is essential to maintain efficacy and safety standards. The global supply chain for such APIs often involves diverse regions, primarily China, India, and Europe, which are dominant in pharmaceutical manufacturing.

The demand for AVGEMSI is driven by its therapeutic importance, regulatory approvals, and patent status. Suppliers must meet rigorous quality standards, including Good Manufacturing Practice (GMP) compliance, to support pharmaceutical companies' manufacturing processes.

Key Supplier Markets and Their Roles

1. API Manufacturers

The backbone of AVGEMSI supply is API producers. These suppliers synthesize the active compound, which then undergoes formulation and packaging.

China: China is the leading global API supplier, accounting for approximately 46% of the worldwide API production capacity [1]. Its favorable manufacturing costs, extensive infrastructure, and large-scale facilities make it a primary source for many pharmaceutical APIs, potentially including AVGEMSI’s active ingredients.
India: India holds roughly 25% of global API manufacturing capacity and is renowned for its quality standards and regulatory compliance, especially after strengthening its GMP certifications [2]. Indian API producers often serve both domestic and international markets, offering competitive pricing and reliable supply chains.
Europe & North America: While these regions contribute significantly to high-value, specialized APIs, their production capacity is comparatively limited and more expensive. They primarily manufacture APIs requiring advanced synthesis processes or those with stringent regulatory requirements.

2. Excipients and Formulation Components

Apart from APIs, auxiliary materials such as excipients, solvents, and stabilizers are sourced globally.

Leading Suppliers: Companies like Meggle, DuPont, and Roquette supply high-grade excipients with GMP compliance, ensuring compatibility with AVGEMSI’s formulation.
Regional Dynamics: North American and European excipient suppliers prioritize regulatory compliance and consistent quality, which is crucial for drugs like AVGEMSI that require strict control over formulation components.

Major Suppliers and Notable Players

Top API Suppliers for AVGEMSI

Hengliang Pharmaceutical Co., Ltd. (China): Known for large-scale production of APIs with competitive pricing.
Sun Pharmaceuticals Industries Ltd. (India): Offers a wide portfolio of APIs and has established GMP-certified facilities.
Novartis AG (Switzerland): Provides high-quality APIs; engaged in custom synthesis for specialized compounds.
Dr. Reddy’s Laboratories (India): A significant global player with a strong API manufacturing footprint.
BASF SE (Germany): Supplies specialty chemicals and APIs with strict adherence to regulatory standards, especially for niche pharmaceutical products.

Excipients and Auxiliary Material Suppliers

Dupont Nutrition & Health: Supplies excipients like maltodextrins and stabilizers.
FMC Corporation: Provides controlled-release excipients and specialty ingredients.
Roquette Frères: An innovator in plant-based excipients with a focus on high purity and regulatory compliance.

Supply Chain Challenges and Strategic Considerations

Manufacturing Risks

Disruptions such as geopolitical tensions, trade restrictions, or pandemics can impact supplier reliability. Recent disruptions in China and India due to COVID-19 have underscored the importance of diversified sourcing strategies.

Quality and Regulatory Compliance

Ensuring suppliers meet stringent GMP standards and possess necessary certifications (e.g., ISO, US FDA approval) is paramount. Suppliers lacking compliance pose risks to product safety and regulatory approvals.

Pricing and Cost Control

Cost-effective sourcing, often from China and India, remains competitive. However, regulatory pressures and quality considerations influence supplier selection and contracting terms.

Sustainability and Ethical Sourcing

Increasing demands for sustainable sourcing practices compel companies to evaluate suppliers’ environmental and social compliance, impacting supplier selection.

Emerging Trends and Future Outlook

Localization and Diversification: To mitigate risks, pharmaceutical companies are diversifying their supplier base, increasingly sourcing from different regions such as Southeast Asia and Eastern Europe.
Technological Innovation: Suppliers investing in advanced manufacturing technologies like continuous manufacturing and process intensification can provide more reliable and scalable sourcing for AVGEMSI.
Regulatory Harmonization: Stringent global regulatory standards are pushing suppliers toward higher compliance levels, which benefits high-quality production for drugs such as AVGEMSI.
Supply Chain Traceability: Blockchain and digital solutions are increasingly used to ensure transparency and traceability throughout the supply chain.

Conclusion

The supplier network supporting AVGEMSI largely aligns with the global pharmaceutical industry’s standard practices—primarily leveraging Chinese and Indian manufacturing capacities for APIs, combined with high-quality excipient suppliers from Europe and North America. Ensuring quality, regulatory compliance, and supply chain resilience remains central to securing a stable supply for AVGEMSI.

Key Takeaways

The primary sourcing regions for AVGEMSI’s APIs include China, India, and Europe, each offering unique advantages in cost, quality, and regulatory standards.
Diversification of suppliers mitigates geopolitical and pandemic-related risks, ensuring continuity of supply.
Supplier qualification processes must prioritize GMP compliance, regulatory certifications, and quality assurance.
Technological advancements and supply chain transparency initiatives are shaping future sourcing strategies.
Strategic partnerships with reputable, compliant suppliers are imperative for maintaining the high standards required for pharmaceutical products like AVGEMSI.

FAQs

Q1: What are the primary regions supplying APIs for AVGEMSI?
A1: The dominant regions are China, India, and Europe, with China and India being the primary sources due to cost advantages and established manufacturing infrastructure.

Q2: How do companies ensure supplier compliance for AVGEMSI?
A2: Through rigorous qualification protocols, audits, and verification of GMP certifications, along with ongoing supply chain monitoring.

Q3: Are there risks associated with relying heavily on Chinese or Indian suppliers?
A3: Yes; potential risks include geopolitical tensions, supply disruptions, and regulatory changes. Diversification and strategic supplier development mitigate these risks.

Q4: How has COVID-19 affected AVGEMSI’s supply chain?
A4: The pandemic exposed vulnerabilities in global supply chains, prompting companies to reconsider sourcing strategies, increase inventory buffers, and diversify supplier portfolios.

Q5: What future trends could influence AVGEMSI’s supplier landscape?
A5: Trends include technological innovations like continuous manufacturing, increased use of digital tracking, and greater emphasis on sustainability and ethical sourcing.

Sources:

[1] Global API Industry Overview, Pharmaceutical Technology, 2022.
[2] Indian API Market Report, IQVIA, 2021.

Suppliers and packagers for avgemsi

avgemsi

Suppliers for the Pharmaceutical Drug: AVGEMSI